# Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis

> **NCT00989807** · — · APPROVED_FOR_MARKETING · sponsor: **Gilead Sciences**

## Conditions studied

- Cystic Fibrosis
- Pseudomonas Aeruginosa

## Interventions

- **DRUG:** Aztreonam lysine

## Key facts

- **NCT ID:** NCT00989807
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2012-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989807, "Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00989807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*